Cyphos 1gm IV Infusion

✔️ Side Effects of Cyphos 1gm IV Infusion

Digestive System:

• Common: Nausea, vomiting, anorexia.
• Rare: Abdominal pain, diarrhea, hemorrhagic colitis, oral ulcers, jaundice.

Skin:

• Common: Alopecia (hair often regrows after treatment, though its texture or color may change).
• Rare: Skin rash, pigmentation changes, nail changes, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Hematopoietic System:

• Common: Leukopenia, neutropenia (linked to infection risk).
• Occasional: Thrombocytopenia, anemia.
• Recovery typically occurs within 7–10 days of stopping therapy.

Urinary System:

• Rare: Hemorrhagic ureteritis, renal tubular necrosis.

Respiratory System:

• Rare: Interstitial pneumonitis, pulmonary fibrosis (with high-dose prolonged use).

Other:

• Rare: Anaphylactic reactions, SIADH (syndrome of inappropriate ADH secretion), fatigue, and malaise.

✔️ Cyclophosphamide Administration and Dosage Guidelines

Oral:

• Preferably taken on an empty stomach, but may be taken with food to reduce gastrointestinal (GI) irritation.
• Ensure adequate fluid intake (at least 2 liters/day for adults).
• Swallow tablets whole; do not crush or chew.

Intravenous (IV) Preparation:

• Maximum concentration: 20 mg/mL (due to solubility limits).
• IV Push: Reconstitute with normal saline (NS). Do not use sterile water for injection (SWI) as it is hypotonic.
• IV Infusion: Reconstitute with SWI to 20 mg/mL concentration and dilute further with compatible fluids such as D5W, NS, or lactated Ringer's solution.
• Administration:
  • Infuse over 1–2 hours for most cases.
  • Doses >500 mg to ~1 g can be administered over 20–30 minutes.

Bladder Toxicity Precaution:

• Increase fluid intake during and 1–2 days after treatment to minimize bladder toxicity.
• High-dose regimens may require aggressive hydration, with or without mesna therapy to prevent urotoxicity.

Adult Dosage

Malignant Diseases:

• IV (Intermittent Therapy): 40–50 mg/kg (400–1800 mg/m²) divided over 2–5 days, repeated every 2–4 weeks.
• IV (Continuous Daily Therapy): 60–120 mg/m²/day (1–2.5 mg/kg/day).
• Oral (Intermittent Therapy): 400–1000 mg/m² divided over 4–5 days.
• Oral (Continuous Daily Therapy): 50–100 mg/m²/day or 1–5 mg/kg/day.

Nephrotic Syndrome:

• 2–3 mg/kg/day for up to 12 weeks when corticosteroids fail.

Non-Hodgkin’s Lymphoma:

• IV: 600–1500 mg/m² combined with other antineoplastics (as part of the CHOP regimen). Dose intensification may be applied as necessary.

Breast Cancer:

• IV: 600 mg/m² in combination with other antineoplastics; dose intensification may also be applied.

Pediatric Dosage

Malignant Diseases:

• IV (Intermittent Therapy): 40–50 mg/kg (400–1800 mg/m²) divided over 2–5 days, repeated every 2–4 weeks.
• IV (Continuous Daily Therapy): 60–120 mg/m²/day (1–2.5 mg/kg/day).
• Oral (Intermittent Therapy): 400–1000 mg/m² divided over 4–5 days.
• Oral (Continuous Daily Therapy): 50–100 mg/m²/day.

Juvenile Idiopathic Arthritis/Vasculitis:

• IV: 10 mg/kg every 2 weeks.

Nephrotic Syndrome:

• 2–3 mg/kg/day for up to 12 weeks when corticosteroids are unsuccessful.

Systemic Lupus Erythematosus:

• IV: 500–750 mg/m² monthly; maximum dose of 1 g/m².

These dosage and administration guidelines should be followed under the close supervision of a healthcare provider to ensure safety and efficacy.

✔️ Overdose Management

There is no specific antidote for Cyphos overdose. Supportive care should include treatment for infections, myelosuppression, or cardiac toxicity, as needed.

✔️ Drug Interactions: Cyphos 1gm IV Infusion

• Phenobarbital: Chronic high doses enhance Cyphos metabolism and leukopenic effects.
• Succinylcholine: Cyphos may potentiate its effects by inhibiting cholinesterase activity. Patients who have received Cyphos within 10 days of anesthesia should alert their anesthesiologist.
• The use of Cyphos alongside other cytotoxic agents may necessitate dose adjustments due to cumulative toxicity.

✔️ Cyphos is contraindicated in:

• Patients with severe bone marrow suppression.
• Those with known hypersensitivity to cyclophosphamide.

✔️ Pregnancy and Lactation

• Pregnancy: Category D. Cyclophosphamide poses risks to fetal development and is contraindicated during pregnancy.
• Lactation: The drug is excreted in breast milk and may cause adverse effects in nursing infants. A decision must be made to either discontinue nursing or the drug.

✔️ Exercise caution in patients with:

• Leukopenia or thrombocytopenia.
• Bone marrow infiltration by tumor cells.
• History of radiation or cytotoxic therapy.
• Impaired liver or kidney function.

✔️ Storage Instructions

Store at temperatures below 25°C in a dry place, protected from light and moisture. Do not freeze.